Titel

Merkliste
1 Ergebnisse

sj-pdf-1-ccx-10.1177_10732748211033497 – Supplemental Mater..:

Shan Xu (454389) ; Ali Sak (11477309) ; Yasin Bahadir Erol (11477312)
https://figshare.com/articles/journal_contribution/sj-pdf-1-ccx-10_1177_10732748211033497_Supplemental_Material_for_Network_Meta-analysis_of_First-Line_Systemic_Treatment_for_Patients_With_Metastatic_Colorectal_Cancer/16676948. , 2021

Link: https://doi.org/10.25384/sage.16676948.v1

RT Journal
T1 <Title>sj-pdf-1-ccx-10.1177_10732748211033497 – Supplemental Material for Network Meta-analysis of First-Line Systemic Treatment for Patients With Metastatic Colorectal Cancer</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftsmithonian:oai:figshare.com:article_16676948&Exemplar=1&LAN=DE
				
A1 Shan Xu (454389)
A1 Ali Sak (11477309)
A1 Yasin Bahadir Erol (11477312)
YR 2021
K1 Oncology and Carcinogenesis not elsewhere classified
K1 triple combination folfoxiri
K1 random effect model
K1 metastatic colorectal cancer
K1 including july 15
K1 estimated hazard ratios
K1 div >< section
K1 conducted including medline
K1 comprehensive literature review
K1 cochrane central registry
K1 antibodies targeting angiogenesis
K1 line systemic therapies
K1 least 1 intervention
K1 line systemic treatment
K1 folfoxiri plus bevacizumab
K1 either chemotherapeutic agents
K1 bayesian network meta
K1 analysis also indicated
K1 146 mcrc patients
K1 os )
K1 progression
K1 network meta
K1 line regimen
K1 treatment strategies
K1 least one
K1 study supported
K1 studies reported
K1 significant advantage
K1 safe strategy
K1 relative efficacy
K1 potentially effective
K1 phase ii
K1 pfs )
K1 overall survival
K1 indirect evidences
K1 improved os
K1 grade 3
K1 free survival
K1 following outcomes
K1 experimental design
K1 direct comparisons
K1 controlled trials
K1 aes )
K1 adverse events
JF https://figshare.com/articles/journal_contribution/sj-pdf-1-ccx-10_1177_10732748211033497_Supplemental_Material_for_Network_Meta-analysis_of_First-Line_Systemic_Treatment_for_Patients_With_Metastatic_Colorectal_Cancer/16676948
LK http://dx.doi.org/https://doi.org/10.25384/sage.16676948.v1
DO https://doi.org/10.25384/sage.16676948.v1
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)